Safety of 48 months of elagolix with add-back therapy for endometriosis-associated pain
This study extends findings from a previously reported 12-month analysis of the efficacy and safety of ELA+AB therapy in premenopausal women with moderate-to-severe endometriosis-associated pain. The safety profile of ELA+AB therapy was generally consistent with that observed in prior studies. BMD remained mostly stable through 48 months of continuous treatment. This analysis represents the longest safety study of ELA+AB therapy to date and supports long-term treatment with ELA+AB therapy.
Authors
- Charles E. Miller (ORCID: https://orcid.org/0000-0002-1892-2818)
- Michael C. Snabes
- Jin Hee Kim (ORCID: https://orcid.org/0000-0003-1204-7079)
- James W. Thomas (ORCID: https://orcid.org/0000-0002-4909-9967)
- James A. Simon
- Anna Chan
Institutions
- George Washington University (US)
- Columbia University Irving Medical Center (US)
- Advocate Lutheran General Hospital (US)
- AbbVie (United States) (US)
- The Advanced IVF Institute (US)
- Columbia University (US)
Publication Details
- Journal
- AJOG Global Reports
- Published
- 2025-11-08
- DOI
- https://doi.org/10.1016/j.xagr.2025.100584
- Citations
- 1
- Primary Topic
- Endometriosis Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.70